Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ORMP's Cash to Debt is ranked higher than
87% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. ORMP: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ORMP' s Cash to Debt Range Over the Past 10 Years
Min: 1.06  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.85
ORMP's Equity to Asset is ranked higher than
75% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ORMP: 0.85 )
Ranked among companies with meaningful Equity to Asset only.
ORMP' s Equity to Asset Range Over the Past 10 Years
Min: 0.85  Med: 0.85 Max: 0.85
Current: 0.85
F-Score: 4
Z-Score: 10.39
WACC vs ROIC
5.07%
-45.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -3001.39
ORMP's Operating margin (%) is ranked lower than
86% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. ORMP: -3001.39 )
Ranked among companies with meaningful Operating margin (%) only.
ORMP' s Operating margin (%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -3001.39
Net-margin (%) -2888.89
ORMP's Net-margin (%) is ranked lower than
86% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. ORMP: -2888.89 )
Ranked among companies with meaningful Net-margin (%) only.
ORMP' s Net-margin (%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -2888.89
ROE (%) -31.42
ORMP's ROE (%) is ranked higher than
51% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. ORMP: -31.42 )
Ranked among companies with meaningful ROE (%) only.
ORMP' s ROE (%) Range Over the Past 10 Years
Min: -8090  Med: -75.21 Max: -31.7
Current: -31.42
-8090
-31.7
ROA (%) -28.29
ORMP's ROA (%) is ranked higher than
50% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. ORMP: -28.29 )
Ranked among companies with meaningful ROA (%) only.
ORMP' s ROA (%) Range Over the Past 10 Years
Min: -468.93  Med: -66.23 Max: -30.04
Current: -28.29
-468.93
-30.04
ROC (Joel Greenblatt) (%) -72.49
ORMP's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. ORMP: -72.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ORMP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -313200  Med: -310.63 Max: 5234
Current: -72.49
-313200
5234
EBITDA Growth (3Y)(%) 8.90
ORMP's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ORMP: 8.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ORMP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.7  Med: 3.35 Max: 57.2
Current: 8.9
-10.7
57.2
EPS Growth (3Y)(%) 5.70
ORMP's EPS Growth (3Y)(%) is ranked higher than
63% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. ORMP: 5.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ORMP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.7  Med: 2.55 Max: 188.4
Current: 5.7
-30.7
188.4
» ORMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ORMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:XENE, OTCPK:CALZF, NAS:DPRX, NAS:CRBP, NAS:AKTX, NAS:CTIC, NAS:SQNM, NAS:MRTX, NAS:CRME, NAS:TTNP, OTCPK:APHQF, OTCPK:SLNCF, NAS:PRQR, OTCPK:EXQNF, NAS:AUPH, OTCPK:NURPF, NAS:GNCA, AMEX:OCX, NAS:ADHD, OTCPK:PHGUF » details
Traded in other countries:OJU1.Germany, ORMP.Switzerland,
Oramed Pharmaceuticals Inc is a pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet.

Oramed Pharmaceuticals Inc was incorporated on April 12, 2002, under the laws of the state of Nevada. It is a pharmaceutical company engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. It filed two additional provisional patents for a suppository application to its technology portfolio. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.

Ratios

vs
industry
vs
history
P/B 3.49
ORMP's P/B is ranked lower than
52% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. ORMP: 3.49 )
Ranked among companies with meaningful P/B only.
ORMP' s P/B Range Over the Past 10 Years
Min: 2.44  Med: 3.42 Max: 3.77
Current: 3.49
2.44
3.77
P/S 371.35
ORMP's P/S is ranked lower than
92% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. ORMP: 371.35 )
Ranked among companies with meaningful P/S only.
ORMP' s P/S Range Over the Past 10 Years
Min: 340.91  Med: 609.00 Max: 930
Current: 371.35
340.91
930
Current Ratio 18.79
ORMP's Current Ratio is ranked higher than
90% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. ORMP: 18.79 )
Ranked among companies with meaningful Current Ratio only.
ORMP' s Current Ratio Range Over the Past 10 Years
Min: 0.13  Med: 8.19 Max: 67.68
Current: 18.79
0.13
67.68
Quick Ratio 18.79
ORMP's Quick Ratio is ranked higher than
90% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. ORMP: 18.79 )
Ranked among companies with meaningful Quick Ratio only.
ORMP' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 8.19 Max: 67.68
Current: 18.79
0.13
67.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 81.70
ORMP's Price/Net Cash is ranked lower than
96% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. ORMP: 81.70 )
Ranked among companies with meaningful Price/Net Cash only.
ORMP' s Price/Net Cash Range Over the Past 10 Years
Min: 2.58  Med: 12.29 Max: 139.2
Current: 81.7
2.58
139.2
Price/Net Current Asset Value 5.41
ORMP's Price/Net Current Asset Value is ranked lower than
55% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. ORMP: 5.41 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ORMP' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.56  Med: 7.77 Max: 94.5
Current: 5.41
2.56
94.5
Price/Tangible Book 3.46
ORMP's Price/Tangible Book is ranked higher than
56% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. ORMP: 3.46 )
Ranked among companies with meaningful Price/Tangible Book only.
ORMP' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.19  Med: 7.41 Max: 76.36
Current: 3.46
2.19
76.36
Price/Projected FCF 12.01
ORMP's Price/Projected FCF is ranked lower than
79% of the 201 Companies
in the Global Biotechnology industry.

( Industry Median: 3.44 vs. ORMP: 12.01 )
Ranked among companies with meaningful Price/Projected FCF only.
ORMP' s Price/Projected FCF Range Over the Past 10 Years
Min: 5.46  Med: 10.10 Max: 18.2
Current: 12.01
5.46
18.2
Price/Median PS Value 0.61
ORMP's Price/Median PS Value is ranked higher than
77% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ORMP: 0.61 )
Ranked among companies with meaningful Price/Median PS Value only.
ORMP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.65  Med: 0.91 Max: 1.16
Current: 0.61
0.65
1.16
Earnings Yield (Greenblatt) (%) -8.17
ORMP's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. ORMP: -8.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ORMP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -666.7  Med: 0.00 Max: 9.3
Current: -8.17
-666.7
9.3

More Statistics

Revenue (TTM) (Mil) $0.29
EPS (TTM) $ -0.69
Beta0.44
Short Percentage of Float4.74%
52-Week Range $4.15 - 10.74
Shares Outstanding (Mil)13.14
» More Articles for NAS:ORMP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of... Jul 28 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events Jul 28 2016
8:19 am Oramed Pharmaceuticals reports additional data from the Phase IIb trial of ORMD-0801 in... Jul 28 2016
Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of... Jul 28 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 27 2016
Oramed Appoints Dr. Roy Eldor as Chief Medical Director Jul 26 2016
Oramed Appoints Dr. Roy Eldor as Chief Medical Director Jul 26 2016
ORAMED PHARMACEUTICALS INC. Financials Jul 12 2016
Oramed reports 3Q loss Jul 06 2016
Oramed reports 3Q loss Jul 06 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Jul 06 2016
The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All Jun 22 2016
Oramed Announces $6.5 Million Milestone Payment from HTIT Jun 21 2016
Oramed Announces $6.5 Million Milestone Payment from HTIT Jun 21 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 16 2016
3 Biotechs That Just Announced Successful Phase 2 Trials Jun 11 2016
Oramed to Present at the American Diabetes Association 76th Scientific Sessions Jun 09 2016
Oramed to Present at the American Diabetes Association 76th Scientific Sessions Jun 09 2016
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure May 23 2016
Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study May 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)